Case Series
Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure
Table 1
Summary of baseline characteristics in five patients after Fontan procedure who were treated with a SGLT-2 inhibitor.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Times of admission means unexpected admission due to not scheduled examination or treatment but cardiovascular symptoms. AP shunt: aortopulmonary shunt; AVSD: atrioventricular septal defect; BMI: body mass index; CI: cardiac index; CKD: chronic kidney disease; CNS: central nervous system; CVP: central venous pressure; DM: diabetes mellitus; DORV: double outlet right ventricle; ECC: extracardiac conduit; EF: ejection fraction; FALD: Fontan-associated liver disease; HLHS: hypoplastic left ventricle; IVCD: inferior vena cava defect; LV: left ventricle; MGA: malposition of the great arteries; PA: pulmonary atresia; PAB: pulmonary arterial banding; PAf: paroxysmal atrial fibrillation; PB: plastic bronchitis; PLE: protein-losing enteropathy; PMI: pacemaker implantation; PS: pulmonary stenosis; TCPS: total cavopulmonary shunt; Valve regurg.: valve regurgitation. |